

# Irina F Sevrioukova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4549309/publications.pdf>

Version: 2024-02-01

51  
papers

2,720  
citations

172386

29  
h-index

182361

51  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apoptosis-Inducing Factor: Structure, Function, and Redox Regulation. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 2545-2579.	2.5	268
2	Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18422-18427.	3.3	240
3	Severe X-Linked Mitochondrial Encephalomyopathy Associated with a Mutation in Apoptosis-Inducing Factor. <i>American Journal of Human Genetics</i> , 2010, 86, 639-649.	2.6	199
4	Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor. <i>American Journal of Human Genetics</i> , 2012, 91, 1095-1102.	2.6	134
5	Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. <i>Dalton Transactions</i> , 2013, 42, 3116-3126.	1.6	133
6	Structural and Mechanistic Insights into the Interaction of Cytochrome P4503A4 with Bromoergocryptine, a Type I Ligand. <i>Journal of Biological Chemistry</i> , 2012, 287, 3510-3517.	1.6	106
7	Photoreduction of the active site of the metalloprotein putidaredoxin by synchrotron radiation. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2007, 63, 951-960.	2.5	97
8	Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 486-491.	3.3	90
9	Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4210-4220.	2.9	88
10	Crystal Structure of Putidaredoxin, the [2Fe-2S] Component of the P450cam Monooxygenase System from <i>Pseudomonas putida</i> . <i>Journal of Molecular Biology</i> , 2003, 333, 377-392.	2.0	86
11	Dissecting Cytochrome P450 3A4-Ligand Interactions Using Ritonavir Analogues. <i>Biochemistry</i> , 2013, 52, 4474-4481.	1.2	77
12	Crystal Structure of Putidaredoxin Reductase from <i>Pseudomonas putida</i> , the Final Structural Component of the Cytochrome P450cam Monooxygenase. <i>Journal of Molecular Biology</i> , 2004, 336, 889-902.	2.0	74
13	Redox-dependent Changes in Molecular Properties of Mitochondrial Apoptosis-inducing Factor. <i>Journal of Biological Chemistry</i> , 2008, 283, 5622-5631.	1.6	71
14	Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3733-3741.	2.9	68
15	Putidaredoxin-to-Cytochrome P450cam Electron Transfer: Differences between the Two Reductive Steps Required for Catalysis. <i>Biochemistry</i> , 2006, 45, 11934-11944.	1.2	65
16	Redox-dependent Structural Reorganization in Putidaredoxin, a Vertebrate-type [2Fe-2S] Ferredoxin from <i>Pseudomonas putida</i> . <i>Journal of Molecular Biology</i> , 2005, 347, 607-621.	2.0	57
17	Interaction of human cytochrome P4503A4 with ritonavir analogs. <i>Archives of Biochemistry and Biophysics</i> , 2012, 520, 108-116.	1.4	54
18	Structural biology of redox partner interactions in P450cam monooxygenase: A fresh look at an old system. <i>Archives of Biochemistry and Biophysics</i> , 2011, 507, 66-74.	1.4	52

#	ARTICLE	IF	CITATIONS
19	Redox-Linked Conformational Dynamics in Apoptosis-Inducing Factor. <i>Journal of Molecular Biology</i> , 2009, 390, 924-938.	2.0	51
20	Structure/Function Relations in AIFM1 Variants Associated with Neurodegenerative Disorders. <i>Journal of Molecular Biology</i> , 2016, 428, 3650-3665.	2.0	48
21	The Putidaredoxin Reductase-Putidaredoxin Electron Transfer Complex. <i>Journal of Biological Chemistry</i> , 2005, 280, 16135-16142.	1.6	45
22	Anion-Dependent Stimulation of CYP3A4 Monooxygenase. <i>Biochemistry</i> , 2015, 54, 4083-4096.	1.2	45
23	High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4. <i>Biochemistry</i> , 2017, 56, 3058-3067.	1.2	40
24	Laser Flash Induced Electron Transfer in P450cam Monooxygenase: Putidaredoxin Reductase-Putidaredoxin Interaction. <i>Biochemistry</i> , 2001, 40, 10592-10600.	1.2	38
25	Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions. <i>Advances in Experimental Medicine and Biology</i> , 2015, 851, 83-105.	0.8	37
26	Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. <i>Journal of the American Chemical Society</i> , 2021, 143, 9191-9205.	6.6	37
27	Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. <i>Cell Chemical Biology</i> , 2017, 24, 1259-1275.e6.	2.5	35
28	Electron Transfer between Cytochrome P450cin and Its FMN-containing Redox Partner, Cindoxin. <i>Journal of Biological Chemistry</i> , 2007, 282, 27006-27011.	1.6	34
29	Crystal Structure of the Putidaredoxin Reductase-Putidaredoxin Electron Transfer Complex. <i>Journal of Biological Chemistry</i> , 2010, 285, 13616-13620.	1.6	30
30	Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules. <i>Biochemistry</i> , 2019, 58, 930-939.	1.2	30
31	Putidaredoxin Reductase, a New Function for an Old Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 25831-25839.	1.6	28
32	Ritonavir Analogues as a Probe for Deciphering the Cytochrome P450 3A4 Inhibitory Mechanism. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 1348-1355.	1.0	28
33	Electron transfer in the ruthenated heme domain of cytochrome P450BM-3. <i>Israel Journal of Chemistry</i> , 2000, 40, 47-53.	1.0	27
34	Key Role of the Adenylate Moiety and Integrity of the Adenylate-Binding Site for the NAD <sup>+</sup> /H Binding to Mitochondrial Apoptosis-Inducing Factor. <i>Biochemistry</i> , 2015, 54, 6996-7009.	1.2	26
35	Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. <i>Molecular Pharmaceutics</i> , 2018, 15, 279-288.	2.3	23
36	Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6 $\beta$ ,7 $\alpha$ -Dihydroxybergamottin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4245.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Stereoselective Oxidation Kinetics of Deoxycholate in Recombinant and Microsomal CYP3A Enzymes: Deoxycholate 19-Hydroxylation Is an In Vitro Marker of CYP3A7 Activity. <i>Drug Metabolism and Disposition</i> , 2019, 47, 574-581.	1.7	17
38	Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength. <i>International Journal of Molecular Sciences</i> , 2021, 22, 852.	1.8	15
39	Production and Characterization of a Functional Putidaredoxin Reductase <sup>+</sup> Putidaredoxin Covalent Complex. <i>Biochemistry</i> , 2010, 49, 58-67.	1.2	14
40	Redox reactions of the FAD-containing apoptosis-inducing factor (AIF) with quinoidal xenobiotics: A mechanistic study. <i>Archives of Biochemistry and Biophysics</i> , 2011, 512, 183-189.	1.4	13
41	Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution. <i>Biochemistry</i> , 2019, 58, 3903-3910.	1.2	12
42	Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4. <i>Biochemistry</i> , 2019, 58, 2077-2087.	1.2	12
43	An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115349.	1.4	11
44	Steroid bioconjugation to a CYP3A4 allosteric site and its effect on substrate binding and coupling efficiency. <i>Archives of Biochemistry and Biophysics</i> , 2018, 653, 90-96.	1.4	8
45	Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5831.	1.8	8
46	Innovative C-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113496.	2.6	7
47	Direct synthesis of $\hat{\pm}$ -thio aromatic acids from aromatic amino acids. <i>Tetrahedron Letters</i> , 2018, 59, 1140-1142.	0.7	6
48	Unexpected Differences between Two Closely Related Bacterial P450 Camphor Monooxygenases. <i>Biochemistry</i> , 2020, 59, 2743-2750.	1.2	6
49	Structural Dynamics of Cytochrome P450 3A4 in the Presence of Substrates and Cytochrome P450 Reductase. <i>Biochemistry</i> , 2021, 60, 2259-2271.	1.2	6
50	Arginines 65 and 310 in Putidaredoxin Reductase Are Critical for Interaction with Putidaredoxin. <i>Biochemistry</i> , 2010, 49, 5160-5166.	1.2	3
51	Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7291.	1.8	3